Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $-4,110,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 600
- Avg volume
- 1,408
- Day's range
- $10.90 – $10.95
- Shares out
- —
- Stochastic %K
- 37%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine impla...
Show more
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- Phone
- 781 552 4452
- Website
- https://www.bonebiologics.com
- Address
- 2 Burlington Woods Drive, Suite 100, Burlington, United States
Latest news
No headlines yet.